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Abstract 
Drug induced exfoliative dermatitis (ED) are a group of rare and severe drug hypersensitivity reactions (DHR) involv‑
ing skin and usually occurring from days to several weeks after drug exposure. Erythema multiforme (EM), Stevens–
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the main clinical presentations of drug induced ED. 
Overall, T cells are the central player of these immune‑mediated drug reactions. Here we provide a systematic review 
on frequency, risk factors, pathogenesis, clinical features and management of patients with drug induced ED.
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Background
Cutaneous drug eruptions are one of the most common 
types of adverse reaction to medications, with an over-
all incidence of 2–3  % in hospitalized patients [1]. In 
particular, drug induced exfoliative dermatitis (ED) are a 
group of rare and more severe drug hypersensitivity reac-
tions (DHR) involving skin and mucous membranes and 
usually occurring from days to several weeks after drug 
exposure [2]. Erythema multiforme (EM), Stevens–John-
son syndrome (SJS) and toxic epidermal necrolysis (TEN) 
are the main clinical presentations of drug induced ED. 
Important data on ED have been obtained by RegiSCAR 
(European Registry of Severe Cutaneous Adverse Reac-
tions to Drugs: www.regiscar.org), an ongoing pharmaco-
epidemiologic study conducted in patients with SJS 
and TEN. Overall, T cells are the central player of these 
immune-mediated drug reactions. Immune-histopatho-
logical features allow to distinguish generalized bullous 
drug eruption from SJS/TEN [3–6]. Still, treatment indi-
cation, choice and dosage remain unclear, and efficacy 
yet unproven. Here we provide a systematic review of 
frequency, risk factors, molecular and cellular mecha-
nisms of reactions, clinical features, diagnostic work-up 
and therapy approaches to drug induced ED.
Epidemiology
Epidemiological studies on EM, SJS and TEN syndromes 
report different results, probably related to several biases, 
such as ethnical differences, diagnostic criteria and 
drug consumption patterns in different socio-economic 
systems. Albeit the lack of epidemiologic data regard-
ing EM, its reported prevalence is less than 1 % [7–10]. 
Several authors report the incidence of hospitalization 
for EM ranging from 0.4–6 cases per million people per 
year of northern Europe [11] to almost 40 cases per mil-
lion people per year of United States [12]. EM usually 
occurs in young adults of 20–40  years of age [13], with 
women affected more frequently than men (1.5:1.0) [14]. 
Recurrence occurs in around one-third of cases [15] and 
there is a genetic predisposition for certain Asian groups 
[16]. Mucosal involvement could achieve almost 65 % of 
patients [17]. EM’s mortality rate is not well reported.
Overall, incidence of SJS/TEN ranges from 2 to 7 cases 
per million person per year [9, 18–20], with SJS the com-
monest [21]. In HIV patients, the risk of SJS and TEN 
have been reported to be thousand-fold higher, roughly 
1 per 1000 per year [19]. Prevalence is low, with mortality 
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of roughly 5–12.5 % for SJS and 50 % for TEN [1, 2]. In 
general, they occur more frequently in women, with 
a male to female ratio of 0.6 [22]. The overall mortality 
rate is roughly 30 %, ranging from 10 % for SJS to more 
than 30 % for TEN, with the survival rate worsening until 
1 year after disease onset [9, 18–21].
Pharmacogenetics studies have found an association 
between susceptibility to recurrent EM in response to 
several stimuli and human leukocyte antigen (HLA) hap-
lotypes of class II, in particular HLA DQB1*0301 [23].
On the other hand, it has been demonstrated that 
genetic predisposition may increase the risk for sulphon-
amide-induced [24] and carbamazepine-induced TEN 
and SJS [25]. Scientific evidences suggest a role for HLAs 
and drug-induced SJS/TEN, although some racial dif-
ferences have been found that can be due to variation of 
frequencies of these alleles and to the presence of other 
susceptibility genes [26]. These studies have confirmed 
an association between carbamazepine-induced SJS/
TEN with HLA-B*1502 allele among Han Chinese [27], 
carbamazepine and HLA-A*3101 and HLA-B*1511 [16], 
phenytoin and HLA-B*1502 [28], allopurinol and HLA-
B*5801 [29]. For carbamazpine, several studies have 
found a common link between specific HLAs and dif-
ferent kinds of cutaneous adverse reactions, as for HLA-
A*3101 in Japanese [30] and Europeans [31]. Because a 
certain degree of cross-reactivity between the various 
aromatic anti-epileptic drugs exists, some HLAs have 
been found to be related to SJS/TEN with two drugs, as 
the case of HLA-B*1502 with both phenytoin and oxcar-
bazepine [32].
Pathogenesis
Apoptosis-inducing factors and lymphocyte-mediated 
cytotoxicity have been deeply investigated in ED. Four 
main pathways have been found to play important roles 
in the pathogenesis of keratinocyte death: (1) Fas-FasL 
interaction, (2) Perforin/granzyme B pathway, (3) Gran-
ulysin and (4) Tumor necrosis factor α (TNF-α) [26].
1. Fas-FasL interaction: Fas is a membrane-bound 
protein that after interaction with Fas-ligand (FasL) 
induces a programmed cell death, through the activa-
tion of intracellular caspases. T and NK lymphocytes 
can produce FasL that eventually binds to target cells. 
In ED increased levels of FasL have been detected 
in patients’ sera [33]. The exact source of FasL pro-
duction has not been yet identified as different 
groups have postulated that the production might be 
sought in keratinocytes themselves [33] or in periph-
eral blood mononuclear cells [34]. In any case all 
authors concluded that the blockage of FasL prevents 
keratinocyte apoptosis [35]. The exact role of FasL 
in the pathogenesis of toxic epidermal necrolysis is 
still questionable especially because a correlation 
between serum FasL levels and disease severity has 
not been established and because its levels have been 
found to be increased also in drug-induced hypersen-
sitivity syndrome and maculopapular eruption [36].
2. Perforin/granzyme B pathway: Nassif and colleagues 
have proposed a role for perforin/grazyme B in 
keratinocyte death [37]. They found that the inhibi-
tion of these molecules could attenuate the cytotoxic 
effect of lymphocytes toward keratinocytes. A corre-
lation between increased levels of perforin/granzyme 
B and the severity of TEN was also described [38].
3. Granulysin: Granulysin is a pro-apoptotic protein 
that binds to the cell membrane by means of charge 
interaction without the need of a specific receptor, 
producing a cell membrane disruption, and leading 
to possible cell death. Chung and colleagues found an 
high expression of this molecule in TEN blister fluid 
[39] and confirmed both in vitro and in vivo its dose-
dependent cytotoxicity [39]. Moreover, after granuly-
sin depletion, they observed an increase in cell viabil-
ity. The serum levels of granulysin were also found to 
be increased in the early stage of SJS/TEN, but not in 
other cutaneous DHR [40].
4. Tumor necrosis factor α: TNF-α seems also to play 
an important role in TEN [41]. The fluid of blisters 
from TEN patients was found to be rich in TNF-α, 
produced by monocytes/macrophages present in 
the epidermis [42], especially the subpopulation 
expressing CD16, known to produce higher levels of 
inflammatory cytokines [43]. TNF-α has a dual role: 
interacts with TNF-R1 activating Fas pathway and 
activates NF-κB leading to cell survival. Although 
the final result of this dual interaction is still under 
investigation, it seems that the combination of TNF-
α, IFN-γ (also present in TEN patients) and the acti-
vation of other death receptors such as TWEAK can 
lead to apoptosis of keratinocytes [44].
A central role in the pathogenesis of ED is played by 
CD8+ lymphocytes and NK cells. Even though there is 
not a significant increase in the number of T cells infil-
trating the skin of TEN patients, it was found that their 
role is crucial, even more than HLAs types. In fact, it was 
demonstrated that the specificity of the TCR is a required 
condition for the self-reaction to occur. In particular, 
a specific T cell clonotype was present in the majority 
of patients with carbamazepine-induced SJS/TEN and 
that this clonotype was absent in all patients tolerant to 
the drug who shared the same HLA with the SJS/TEN 
patients [45]. The enhanced activation of CD8 T cells 
seems also to be influenced by the impaired function of 
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CD4 + CD25 + FoxP3 + Treg cells found in the periph-
eral blood of TEN patients in the acute phase [46].
In addition to all these mechanisms, alarmins, endoge-
nous molecules released after cell damage, were found to be 
transiently increased in SJS/TEN patients, perhaps amplify-
ing the immune response, including α-defensin, S100A and 
HMGB1 [47]. These molecules may play a role in amplify-
ing the immune response and in increasing the release of 
other toxic metabolites from inflammatory cells [48].
Histologic features
Given the different histopathological features of the EM, 
SJS and TEN, we decided to discuss them separately.
EM
In EM a lymphocytic infiltrate (CD8+ and macrophages), 
associated with vacuolar changes and dyskeratosis of 
basal keratinocytes, is found along the dermo-epidermal 
junction, while there is a moderate lymphocytic infiltrate 
around the superficial vascular plexus [20]. Partial to full 
thickness epidermal necrosis, intraepidermal vesiculation 
or subepidermal blisters, due to spongiosis and to the cel-
lular damage of the basal layer of the epidermis, can be 
present in the advanced disease [49] Occasionally, severe 
papillary edema is also present [20]. The dermis shows an 
inflammatory infiltrate characterized by a high-density 
lichenoid infiltrate rich in T cells (CD4+ more than CD8+) 
with macrophages, few neutrophils and occasional eosino-
phils; the latter especially seen in cases of DHR [5, 50].
SJS
The SJS histology is characterized by a poor dermal 
inflammatory cell infiltrate and full thickness necrosis of 
epidermis [20, 49]. The epidermal-dermal junction shows 
changes, ranging from vacuolar alteration to subepidermal 
blisters [20]. The dermo-epidermal junction and epidermis 
are infiltrated mostly by CD8+ T lymphocytes whereas 
dermal infiltrate, mainly made from CD4+ T lympho-
cytes, is superficial and mostly perivascular [20, 51].
TEN
TEN is characterized by full-thickness epidermal necro-
sis with an evident epidermal detachment and sloughing 
caused by necrosis of keratinocytes following apoptosis 
[49, 52]. It’s also characterized by a cell-poor infiltrate, 
where macrophages and dendrocytes with a strong 
TNF-α immunoreactivity predominate [6, 50].
Clinical manifestations and culprit agents
EM is a self-limited skin condition mainly associated 
with infections and drugs [53, 54]. It has a wide spectrum 
of severity, and it is divided in minor and major (EMM). 
The former is usually a recurring, localized eruption 
of the skin characterized by pathognomonic target or 
iris lesions, with minimal or no mucosal involvement 
(Fig.  1). EMM is a clinically severe, potentially life-
threatening, extensive sloughing of epidermis, generally 
involving mucosal tissue. In EMM lesions typically begin 
on the extremities and sometimes spread to the trunk. 
Infectious agents are the major cause of EM, in around 
90 % of cases, especially for EM minor and in children. 
Herpes simplex virus (HSV) 1 and 2 are the main trig-
gers in young adults (>80  % of cases), followed by 
Epstein-Barr virus (EBV), and Mycoplasma pneumonia 
[55–58]. Among drug related cases, the main triggering 
factors are sulfonamides, nonsteroidal anti-inflammato-
ries (NSAIDs), penicillins, and anticonvulsants (Table 1) 
[59]. Neoplastic conditions (renal and gastric carcinoma), 
autoimmune disease (inflammatory bowel disease), HIV 
infection, radiation, and food additives/chemicals have 
been reported to be predisposing factor [59].
SJS and TEN are two overlapping syndromes resem-
bling severe burn lesions and characterized by skin 
detachment. When less than 10  % of the body surface 
area (BSA) is involved, it is defined SJS, when between 10 
and 30 % of BSA it is defined overlapping SJS/TEN, when 
more than 30 % of BSA, TEN [2] (Additional file 1: Fig-
ure S1, Additional file 2: Figure S2). SJS/TEN syndrome 
is associated with severe blistering, mucocutaneous peel-
ing, and multi-organ damage and could be life threaten-
ing. TEN is also known as “Lyell syndrome”, since it was 
first described by Alan Lyell in 1956 [2, 60].
Fig. 1 Erythema multiforme (photo reproduced with permission of 
Gary White, MD): typical target lesions (white arrows) together with 
atypical two‑zoned lesions (black arrows)
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Unlike EMM, SJS and TEN are mainly related to medi-
cation use. The strength of association with the devel-
opment of SJS/TEN may vary among countries and 
historical periods, reflecting differences in ethnicities and 
prescription habits among the studied populations [61–
64]. Exposure to anticonvulsivants (phenytoin, phenobar-
bital, lamotrigine), non-nucleoside reverse transcriptase 
inhibitors (nevirapine), cotrimoxazole and other sulfa 
drugs (sulfasalazine), allopurinol and oxicam NSAIDs 
[2] confers a higher risk of developing SJS/TEN. Several 
authors reported also an increased incidence for ami-
nopenicillins, cephalosporins, and quinolones [61, 62]. 
Drugs such as paracetamol, other non-oxicam NSAIDs 
and furosemide, bringing a relatively low risk of SJS/
TEN a priori, are also highly prevalent as putative cul-
prit agents in large SJS/TEN registries, due to their wide-
spread use in the general population [63, 64] (Table  1). 
Rarely, Mycoplasma pneumoniae, dengue virus, cyto-
megalovirus, and contrast media may be the causative 
agent of SJS and TEN [22, 65–67].
It is not completely clear whether EM and SJS are sep-
arate clinical entities or if they represent two different 
expressions of a single disease process. However, accord-
ing to a consensus definition [54], EMM syndrome has 
been separated from SJS/TEN spectrum.
Diagnosis E prognosis
Prodromal and acute phase
During the acute reaction, diagnosis of ED is mainly 
based on clinical parameters. Initial symptoms could 
be aspecific, as fever, stinging eyes and discomfort upon 
swallowing, occurring few days before the onset of 
mucocutaneous involvement. Early sites of skin involve-
ment include trunk, face, palms and soles and rapidly 
spread to cover a variable extension of the body. EMM 
is characterizes by target lesions, circular lesions of 
1-2 cm of diameter, that are defined as typical or atypi-
cal that tends to blister. Typical target lesions consist 
of three components: a dusky central area or blister, a 
dark red inflammatory zone surrounded by a pale ring 
of edema, and an erythematous halo on the periphery. 
Atypical target lesions manifest as raised, edematous, 
palpable lesions with only two zones of color change 
and/or an extensive exanthema with a poorly defined 
border darker in the center  (Fig.  1). In SJS and TEN 
mucosal erosions on the lips, oral cavity, upper airways, 
conjunctiva, genital tract or ocular level are frequent 
[60, 68–70].
Allergy workout
In acute phase it is crucial to assess the culprit agent, in 
particular when the patient was assuming several drugs 
at time of DHR. First of all, Sassolas and coauthors pro-
posed an algorithm of drug causality (ALDEN) in order 
to improve the individual assessment of drug causality in 
TEN and SJS [71]. ALDEN has shown a good accuracy 
to assess drug causality compared to data obtained by 
pharmacovigilance method and case–control results of 
the EuroSCAR case–control analysis for drugs associated 
with TEN.
In vivo tests
Diagnosis in a routine setting is based on patch test (PT) 
while skin test (prick and intradermal tests) with a delayed 
reading are contraindicated in these patients [72]. PTs 
have to be performed at least 6 months after the recovery 
Table 1 Most common culprit drugs in SJS/TEN and EM
Drugs associated with Stevens–Johnson syndrome and toxic epi‑
dermal necrolisis
Risk a 
priori
Preva‑
lence 
in SJS/
TEN reg‑
istries
Extension 
of employ‑
ment
Probable/
very prob‑
able causality 
in multicenter 
trials
Allopurinol Very high Very high Widespread Frequent
Anticonvulsants
Carbamazepine
Lamotrigine
Phenobarbital
Phenytoin
Valproic Acid
Very high Very high Widespread Frequent
NSAIDs Variable High Widespread Variable
Oxicam NSAIDs Very high Low Limited Frequent
Sulfonamides
Cotrimoxazole
Sulfadiazine
Sulfasalazine
Others
High High Widespread Frequent
Non-sulfa antibiotics
Aminopenicil‑
lins
Low Medium Widespread Non frequent
Cephalosporins Medium Medium Widespread Non frequent
Quinolones Medium Medium Widespread Moderately 
frequent
Macrolides Medium Medium Widespread No
Tetraciclines Medium Low Medium Frequent
Nevirapine High High Limited Frequent
Pantoprazole Unknown Low Widespread ND
Paracetamol Low High Widespread Non freqeuent
Furosemide Low Variable Widespread ND
Sertraline High Low Medium Frequent
Drugs associated with erythema multiforme
Sulfonamides
NSAIDs
Anticonvulsants
Antibiotics (mainly penicillins)
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of the reaction, and show a variable sensitivity consider-
ing the implied drug, being higher for beta-lactam, glyco-
peptide antibiotics, carbamazepine, lamotrigine, proton 
pump inhibitors, tetrazepam, trimethoprim—sulfametox-
azole, pseudoephedrine and ramipril [73–76].
In vitro tests
Lymphocyte transformation test (LTT) performed as 
described by Pichler and Tilch [77] shows a lower sensi-
tivity in severe DHR compared to less severe DHR [78] 
but, if available, should be performed within 1 week after 
the onset of skin rash in SJS and TEN [79]. A promising 
and complementary in vitro tool has been used by Polak 
ME et  al. [80], which consists of the determination of 
IFNγ and IL4 by ELISpot (Enzyme-linked immunospot 
assay), allowing to increase the sensitivity of LTT during 
acute DHR (82 versus 50 % if compared to LPA).
Prognosis
A severity-of-Illness score for toxic epidermal necrolysis 
(SCORTEN) has been proposed and validated to predict 
the risk of death at admission [81]. The SCORTEN scale 
is based on a minimal set of parameters as described in 
the following table. For the calculation, available values 
on vital and laboratory parameters within the first 3 days 
after admission to the first hospital are considered when 
the reaction started outside the hospital (community 
patients) or at the date of hospitalization for in-hospital 
patients. Considered variables in SCORTEN are shown 
in Table 2. Mortality rate of patients with TEN has shown 
to be directly correlated to SCORTEN, as shown in Fig. 2.
Differential diagnosis
As described in Table  3, major differential diagnosis of 
EM and SJS/TEN are (1) staphylococcal scalded skin syn-
drome (SSSS), (2) autoimmune blistering diseases and dis-
seminated fixed bullous drug eruption, (3) others severe 
delayed DHR [6, 70, 82] (4) Graft versus host disease
1) SSSS is characterized by periorificial face scabs, de-
epithelialization of friction zones and conspicuous 
desquamation after initial erythroderma. Trigger is 
an exotoxin released by Staphylococcus aureus [83]. 
A useful sign for differential diagnosis is the absence 
of mucosal involvement, except for conjunctiva. Main 
discriminating factors between EMM, SJS, SJS-TEN, 
TEN and SSSS is summarized in Table 3 [84].
2) Pemphigus vulgaris, paraneoplastic pemphigus, bul-
lous pemphigoid and linear IgA dermatosis have to 
be considered. In order to rule out autoimmune blis-
tering diseases, direct immune fluorescence staining 
should be additionally performed to exclude the pres-
ence of immunoglobulin and/or complement depo-
sition in the epidermis and/or the epidermal-dermal 
zone, absent in ED. The Nikolsky’s sign is not specific 
for SJS/TEN, in fact it is present also in auto-immune 
blistering diseases like pemphigus vulgaris. Bullous 
pemphigoid is characterized by large, tense bullae, but 
may begin as an urticarial eruption. Linear IgA der-
matosis most commonly presents in patients older 
than 30 years. The lesions consist of pruritic, annular 
papules, vesicles, and bullae that are found in groups, 
clinically it is similar to dermatitis herpetiformis, 
without a gluten-sensitive enteropathy [85]. Bullous 
dermatoses can be debilitating and possibly fatal. 
Pemphigus vulgaris usually starts in the oral mucosa 
followed by blistering of the skin, which is often pain-
ful. Paraneoplastic pemphigus is associated with neo-
plasms, most commonly of lymphoid tissue, but also 
Waldenström’s macroglobulinemia, sarcomas, thymo-
mas and Castleman’s disease.
3) Other delayed DHR
a. Acute generalized exanthematous pustulosis (AGEP) 
is characterized by acute erythematous skin lesions, 
generally arising in the face and intertriginous areas, 
subsequently sterile pinhead-sized nonfollicular pus-
tules arise and if they coalesce, may sometimes mimic 
a positive Nikolsky’s sign and in this case the condi-
tion may be misinterpreted as TEN [86].
Table 2 The SCORTEN variables
SCORTEN variables
Age ≥40 years 1
Involved BSA at day 1 ≥10 % 1
Presence of cancer or malignancy 1
Heart rate ≥120 beats per minute 1
Serum urea level ≥10 mmol/L 1
Serum bicarbonate level <20 mmol/L 1
Serum glucose ≥14 mmol/L 1
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Fig. 2 Mortality rate of patients with TEN has shown to be directly 
correlated to SCORTEN. Adapted from Ref. [81]
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b. Drug reaction with Eosinophilia and systemic symp-
toms (DRESS) syndrome can mimic SJS and TEN 
in the early phases, since ED can occur together 
with the typical maculo-papular rash. In contrast 
with DRESS, eosinophilia and atypical lymphocytes 
are not described in patients with SJS or TEN. Both 
DRESS and SJS may have increased liver enzymes 
and hepatitis, but they occur in only 10 % of cases of 
SJS compared to 80 % of DRESS. Interstitial nephritis 
is common in DRESS syndrome, occurring roughly 
in 40  % of cases, whereas pre-renal azotemia may 
occur in SJS and TEN.
4) Graft versus host disease (GVHD) Acute GVHD usu-
ally happens within the first 6  months after a trans-
plant. Common acute symptoms include abdominal 
pain or cramps, nausea, vomiting, and diarrhea, jaun-
dice, skin rash and eyes dryness and therefore could 
mimic the prodromal and early phase of ED. The 
diagnosis of GVDH requires histological confirmation 
[87]. 
Management and therapy
The therapeutic approach of EMM, SJS, TEN depends 
on extension of skin, mucosal involvement and sys-
temic patient’s conditions. A multidisciplinary team 
is fundamental in the therapeutic management of 
patients affected by exfoliative DHR. The team should 
include not only physicians but also dedicated nurses, 
physiotherapists and psychologists and should be 
instituted during the first 24  h after patient admis-
sion. Patients present an acute high-grade of skin and 
mucosal insufficiency that obviously leads to great 
impairment in the defenses against bacteria that nor-
mally live on the skin, increasing the high risk of 
systemic infections. Moreover, transpiration and ther-
moregulation are greatly impaired with an elevated loss 
of fluids, proteins and electrolytes through the dam-
aged skin and mucosae. For these reasons, patients 
should be admitted to intensive burn care units or in 
semi-intensive care units where they may have access 
to sterile rooms and to dedicated medical personnel 
[49, 88].
Patients can be extremely suffering because of the pain 
induced by skin and mucosal detachment. They usually 
have fever, are dyspneic and cannot physiologically feed. 
The most important actions to do are listed in Fig. 2, and 
described below.
a) Immediate individuation and interruption of the culprit 
agent
As written before, Sassolas B. et  al. [71] realized an 
algorhitm named ALDEN (algorithm of drug causal-
ity for epidermal necrolysis) which helps to establish a 
cause/effect relationship as “probable” or “very probable” 
in 70 % of cases. All non-indispensable drugs have to be 
stopped because they could alter the metabolism of the 
culprit agent.
Table 3 Differential diagnosis in a patient with suspected exfoliative dermatitis
Pathological condition Pattern of skin lesions Body surface area 
with epidermal detach‑
ment (%)
Trigger Distribution of lesions
Erythema multiforme 
major (EMM)
Typical and atypical target papules and 
plaques, minimum involvement of 
mucous membranes (especially oral 
mucosae)
<10 Infection (Mycoplasma 
pneumoniae, Herpes 
simplex), drugs
Predominantly acrally 
distributed, i.e., begin 
on hands and feet
Stevens–Johnson syn‑
drome (SJS)
No target lesions typical/atypical target 
lesions flattened, cotton wool spots 
purple confluent in the skin of the 
face and trunk, serious eruptions 
mucous membranes at the level of 
one or more sites
<10 Drugs Diffuse. The eruption 
begins on the trunk
Overlap syndrome 
between Stevens–John‑
son and Toxic Epidermal 
Necrolysis (SJS/TEN)
No target lesions/typical target lesions/
atypical target lesions flattened
Between 10 and 30 Drugs Diffuse. The eruption 
begins on the trunk
Toxic epidermal necrolysis 
(TEN)
No target lesions/typical target lesions/
atypical target lesions flattened; 
begins with severe mucosal erosions 
and progresses to a detachment 
spread and generalized epidermis.
>30 Drugs Diffuse. The eruption 
begins on the trunk
Staphylococcical scalded 
skin syndrome (SSSS)
Variable detachment between the 
stratum granulosum and the stratum 
corneum
Variable Bacterial infection 
(Staphylococci)
Diffuse. No mucosal 
involvement except for 
conjunctiva
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b) Evaluation of the skin and mucosal involvement
Dermatologist and/or allergist should confirm the diag-
nosis, individuate the culprit agent, give indications 
about skin management and necessity to obtain the con-
sultation  of  the ENT specialist, the gynecologist/urolo-
gist, the ophthalmologist and/or the pulmonologist in the 
case of mucosal involvement.
c) First‑line interventions
Patient must be placed in an antidecubitus fluidized 
bed and room temperature must be kept at 30–32 °C in 
order to slow catabolism and reduce the loss of calories 
through the skin [89]. All the linen must be sterile. It is 
necessary to obtain as soon as possible a central venous 
access and to start a continuous monitoring of vital signs. 
In case of an oral mucositis that impairs nutrition, it is 
indicated to position a nasogastric tube. Also a vesical 
catheter should be placed to avoid urethral synechiae and 
to have a precise fluid balance. In case of a respiratory 
failure, oxygen should be administrated and a NIMV may 
be required. Temporary tracheostomy may be necessary 
in case of extended mucosal damage. In serious cases 
invasive ventilation can be necessary for ARDS. It is also 
extremely important to obtain within the first 24 h cul-
tural samples from skin together with blood, urine, nasal, 
pharyngeal and bronchus cultures. Ophthalmologic con-
sultations must be repeated at fixed intervals to avoid the 
appearance of conjunctival irreversible complications 
such as chronic conjunctivitis with squamous metapla-
sia, trichiasis, symblepharon, punctate keratitis and sicca 
syndrome. Gynecologist consultation is required for 
avoiding the appearance of vaginal phimosis or sinechias.
d) Prophylactic, supportive and complications therapy
 1. Hydration and hemodynamic balance. Fluid bal-
ance is a main focus. Once established the percent-
age of the involved skin, lactate Ringer infusion of 
1–2 mL/Kg/ % of involved skin must be started dur-
ing the first 24 h [91]. The velocity of infusion should 
be regulated according to patients arterial pressure 
with the aim of 30 mL/h urinary output (1 mL/kg/h 
in case of a child). Blood gas analysis, glucose and 
creatinine levels together with electrolytes should be 
evaluated and therapy should be modified accord-
ingly. Vasoactive amines may be necessary in case 
of shock. Albumin is recommended only is albumin 
serum level is <2.5 mg/dL. Furosemide or ethacrynic 
acid may be required to maintain an adequate uri-
nary output [90].
 2. Nutritional support. An increased metabolism is typ-
ical of patients with extended disepithelizated areas. 
This hypermetabolic state is also furtherly increased 
by the inflammation present in affected areas. Early 
enteral nutrition has also a protective effect on the 
intestinal mucosa and decreases bacterial colo-
nization. Usually the amount of calories is 1500–
2000 kcal/day and the velocity of infusion is gradu-
ally increased based on patients tolerability [92].
 3. Gastric protection. To avoid the appearance of gas-
tric stress ulcer it is recommended to start a therapy 
with intravenous proton pump inhibitors.
 4. Anticoagulation therapy. For the prevention of deep 
venous thrombosis; usually low molecular weight 
heparin at prophylactic dose are used.
 5. Antipyretic therapy. It is recommended to use 
1.5  mg/kg hydrocortisone. If necessary, it can be 
repeated every 6–8 h. NSAIDs should be avoided as 
they can induce ED as well.
 6. Painkiller therapy. Intravenous administration is rec-
ommended. In more severe cases continuous iv ther-
apy can be necessary. Most common used drugs are: 
morphine, fentanyl, propofol and midazolam.
 7. Antibiotic therapy. It is not recommended to use 
prophylactic antibiotic therapy. It should be used 
only in case of a documented positivity of cultural 
samples. If there is a high suspicion of infection 
without a documented source of infection, broad 
range empiric therapy should be started.
 8. Antiviral therapy. Ganciclovir and cidofovir should be 
used when polymerase-chain reactions (PCR) on 
peripheral blood or other biological sample identifies 
a viral reactivation (HHV6, HHV7, EBV and CMV). In 
more severe cases antiviral therapies should be given 
together with intravenous immunoglobulins [93].
 9. Growth-factors (G-CSF). It recommended to used 
G-CSF in patients with febrile neutropenia [94, 95].
 10. Plasmapheresis. It should be considered only once 
the patient is stable and if the skin damage is still 
ongoing and doesn’t respond to other conventional 
therapies (corticosteroids or IVIG). Plasmapher-
esis may have a role in the treatment of ED because 
it removes Fas-L [96], other cytokines known to be 
implied in the pathogenesis (IL-6, IL-8, TNF-α) [97, 
98]. Moreover Mawson A and colleagues hypoth-
esized that the efficacy of plasmapheresis is able to 
reduce serum level of vitamin A. In patients with 
SJS/TEN increased serum levels of retinoid acid have 
been found. These levels could reflect the interaction 
between culprit drugs and aldehyde dehydrogenase 
that is the enzyme which metabolizes retinoid acid. 
Increased level of retinoid acid could be responsible 
for keratinocytes apoptosis [99].
 11. Topical treatment. Patients must be cleaned in the 
affected areas until epithelization starts. In spared 
areas it is necessary to avoid skin detachment. It is 
also recommended to void larger vesicles with a 
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syringe. It is important to protect the damaged skin 
with sterile fat dressing especially in the genital area. 
5  % silver nitrate compresses have antiseptic prop-
erties. Synthetic bilaminar membranes with silver 
nitrate have also a role in skin repairing and avoid 
protein loss through the damaged skin [100, 101]. 
It is advised against the use of silver sulfadiazine 
because sulphonamide can be culprit agents. Autolo-
gous transplantation of mesenchymal umbilical cord 
cells seems also to be highly efficacious [102]. Accu-
rate eye cleaning with saline solution is fundamental 
for the prevention of synechiae and for reducing cor-
neal damage. In more severe cases corneal protective 
lens can be used. It could also be useful to use artifi-
cial tears and lubricating antiseptic gels. The applica-
tions of topical cyclosporine and autologous serum 
have also been showed to be useful in refractory 
cases [103]. Oral hygiene with antiseptic and pain-
killer mouthwash (chlorhexidine +  lidocaine + alu-
minum hydroxide) together with aerosol therapy 
with saline and bronchodilators can reduce upper 
airways symptoms.
e) Anti‑inflammatory and systemic immunosuppressive 
therapy
It is important to take into consideration the mechanism 
of action of the different drugs in the pathogenesis of ED 
[104].
Systemic corticosteroids: These are the most common 
used drugs because of their known anti-inflammatory 
and immunosuppressive effect through the inhibition 
of activated cytotoxic T-cells and the production of 
cytokines. Corticosteroids could also reduce the amount 
of keratinocytes apoptosis and the activation of caspases 
[105]. In EMM their efficacy is demonstrated in control-
ling the evolution of the disease [106]. In SJS, SJS/TEN 
and TEN the efficacy of corticosteroids is far from being 
demonstrated. Recently, a meta-analysis based on 6 ret-
rospective studies evaluating the role of corticosteroids 
alone or together with IVIG has been published [107]. In 
this study, 965 patients were reviewed. The authors con-
cluded that they couldn’t demonstrate corticosteroids 
efficacy in monotherapy, but the use of steroid alone is 
not linked to an increased risk of mortality due to infec-
tive complications [108, 109].
The most commonly used steroids were methylpred-
nisolone, prednisolone and dexamethasone. The induc-
tion dosage in EMM is usually 1 mg/kg/day that should 
be maintained until a complete control of the skin is 
obtained. The taper of steroid therapy should be grad-
ual [93]. In most severe cases the suggested dosage is 
iv 1–1.5 mg/kg/day. Iv bolus of steroid (dexamethasone 
100–300 mg/day or methylprednisolone 250–1000 mg/
day) for 3 consecutive days with a gradual taper ster-
oid therapy is sometimes advised. A switch to oral 
therapy can be performed once the mucosal conditions 
improve.
If after 4 days there is not an improvement it is advised 
to consider the association of steroid or its replacement 
with one of the following drugs [49, 93]:
Intravenous immunoglobulins (IVIG): play their role 
through the inhibition of Fas–Fas ligand interaction that 
it is supposed to be the first step in keratinocytes apop-
tosis [33]. A recently published meta-analysis by Huang 
[110] and coworkers on IVIG in SJS/SJS-TEN/TEN 
reviewed 17 studies with 221 patients and compared the 
results obtained with high-dosage IVIG (>2  g/kg) com-
pared to lower-dosage IVIG (<2 g/kg). 12 out of 17 stud-
ies concluded for a positive role of IVIG in ED. In the 5 
studies that concluded negatively for IVIG, the dosage 
was below 0.4 g/kg/day and treatment was maintained for 
less than 5 days. Schwartz RA et al. [49] confirmed these 
results and even suggested that higher dosage regimen 
with 2.7–4 g/kg seem to be more effective in survival out-
come. A recent review [111] on 33 pediatric cases of TEN 
and 6 cases of SJS/TEN overlap showed that therapy with 
IVIG with a dosage of 0.25–1.5 g/kg for 5 days resulted 
in 0 % mortality rate and faster epithelization. In conclu-
sion, therapy wth IVIG should be started within the first 
5 days and an high-dosage regimen should be preferred 
(2.5–4  g/kg for adults and 0.25–1.5  g/kg in children 
divided in 3–5 days).
Cyclosporine A (Cys A): Cys A works through the inhi-
bition of calcineurin, that is fundamental for cytotoxic T 
lymphocytes activation. In an open trial on cyclosporine 
in 29 patients with TEN, the use of Cys A for at least 
10  days led to a rapid improvement without infective 
complications [112]. Kirchhof MG et al. [113] retrospec-
tively compared mortality in 64 patients with ED treated 
either with iv or oral Cys A (3–5 mg/kg) or IVIG (2–5 g/
Kg). The authors concluded for a potential beneficial 
effect of Cys A and a possible improvement in survival 
compared to IVIG. In conclusion we suggest that ther-
apy with cyclosporine is valuable option with a dosage of 
3–5 mg/kg oral or iv for 7 days.
Anti-TNF-alpha drugs: 
 – Infliximab: chimeric IgG monoclonal anti-TNF-α anti-
body. It was used with success in different case reports 
[114–116]. The administration of a single dose of 5 mg/
kg was able to stop disease progression in 24 h and to 
induce a complete remission in 6–14 days. Infliximab 
was used in cases refractory to high-dosage steroid 
therapy and/or IVIG.
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 – Etanercept: monoclonal antibody against the TNF-α 
receptor. Paradisi et al. [117] described a cohort of ten 
patients affected by TEN treated with a single dose of 
etanercept 50 mg sc with a rapid and complete resolu-
tion and without adverse events.
Even though there is a strong need for randomized tri-
als, anti-TNF-α drugs, in particular a single dose of inf-
liximab 5  mg/kg ev or 50  mg etanercept sc should be 
considered in the treatment of SJS and TEN, especially 
the most severe cases when IVIG and intravenous corti-
costeroids don’t achieve a rapid improvement.
Conclusions
EDs are serious and potentially fatal conditions. Their 
occurrence can be prevented by avoiding drug over-pre-
scription and drug associations that interfere with the 
metabolism of the most frequent triggers [118]. This is 
particularly true for patients with many comorbidities 
and poli-drug therapy, where it is advisable to monitor 
liver and kidney toxicity and to avoid Vitamin A excess 
[99]. Genotyping is recommended in specific high-risk 
ethnic groups (e.g. asiatic) before starting therapies with 
possible triggers (e.g. HLA-B1502, HLA-B5701, HLA-
B5801 and carbamazepine, abacavir, and allopurinol, 
respectively).
Once ED has occurred, it has to be managed in the 
adequate setting with a multidisciplinary approach, and 
every effort has to be made to identify and avoid the 
trigger and to prevent infectious and non-infectious 
complications. Supportive and specific care includes both 
local and systemic measures, as represented in Fig. 3. For 
SJS/TEN, corticosteroids are the cornerstone of treat-
ment albeit efficacy remains unclear. Despite improved 
knowledge of the immunopathogenesis of these condi-
tions, immune-modulatory therapies currently used have 
not been definitively proved to be efficacious [49, 107], 
and new strategies are urgently needed.
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